Targets to Therapies: Aggregation and Synuclein Biology Target Validation
Offered by The Michael J Fox Foundation · New York, NY
About this opportunity
The Targets to Therapies Program seeks to build a robust evidence base for aggregation and synuclein biology targets with high potential relevance to Parkinson's disease. Funding will support projects to clarify human relevance, define mechanism in Parkinson's-relevant contexts, establish target engagement or develop enabling tools and assays.
How to apply
Applications are handled on the funder's own website. Review the full guidelines and apply here: michaeljfox.org/funding-opportunities. Confirm the deadline and eligibility directly with The Michael J Fox Foundation before applying.
See The Michael J Fox Foundation's full giving profile — its grant history, top recipients, and other funding priorities.
Is this grant a fit for your nonprofit?
Before you spend hours on an application, know whether it's worth it. Bespoke Grants scores any open RFP against your mission, budget, and service area — and finds the other funders you're missing. Free, no credit card.
Check my fit & find more grants →Other open opportunities from The Michael J Fox Foundation
The Michael J Fox Foundation currently lists 6 open opportunities in our index.
- Targets to Therapies: Mitochondrial Target Validation
- Access Advocate for Clinical Research Participation
- Parkinson's Disease Proteoforms Program
- GBA1 Parkinson's Disease Research Catalyst Program
- Targets to Therapies: Endolysosomal Target Validation
Frequently asked questions
- What is the deadline for Targets to Therapies: Aggregation and Synuclein Biology Target Validation?
- The application deadline is May 27, 2026. Deadlines can change — always confirm directly with The Michael J Fox Foundation before applying.
- How much funding is available?
- The award range is $250K – $2.0M.
- Where do I apply?
- Applications are submitted through The Michael J Fox Foundation's own website or process — see the "How to apply" section above.